Ignite Creation Date:
2024-05-05 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00509145
Status:
COMPLETED
Last Update Posted:
2021-11-02
First Post:
2007-07-27
Brief Title:
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis RRMS
Sponsor:
Teva Branded Pharmaceutical Products RD Inc
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A Multinational Multicenter Randomized Double-blind Parallel-group Placebo-controlled Study to Evaluate the Safety Tolerability and Efficacy of Daily Oral Administration of Laquinimod 06 mg in Subjects With RRMS
Status:
COMPLETED
Status Verified Date:
2021-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ALLEGRO
Brief Summary:
Determination the efficacy of daily oral treatment with laquinimod 06 mg capsules as compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis RRMS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRACT 2007-003226-19 | None | None | None |